New Releases from NCBI BookshelfIsatuximab (Sarclisa): Indication: In combination with bortezomib, lenalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant: Reimbursement Recommendation [Internet].​Isatuximab (Sarclisa): Indication: In combination with bortezomib, lenalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant: Reimbursement Recommendation [Internet].

By /

Canada’s Drug Agency (CDA-AMC) recommends that Sarclisa be reimbursed by public drug plans for the treatment of patients with newly diagnosed multiple myeloma (MM) who are not eligible for autologous stem cell transplant (ASCT) if certain conditions are met.

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Useful Links

NEWREDMARS SKILL AND RESEARCH        FOUNDATION

Registration No: 771800548      Contact Number : +91-8249516996

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Scroll to Top